Research Topics
Genomes and GenesSpecies | Luigi GennariSummaryAffiliation: University of Siena Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetesLuigi Gennari
Department of Internal Medicine Endocrine Metabolic Sciences, and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy
J Clin Endocrinol Metab 97:1737-44. 2012..26; P = 0.09) and DM2 (r = 0.32; P = 0.07) cohorts. Conclusions: These findings suggest that sclerostin is increased in DM2. Moreover, the transcriptional suppression of sclerostin production by PTH might be impaired in both DM1 and DM2...- Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosisLuigi Gennari
University of Siena, Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Policlinico Le Scotte 53100 Siena, Italy
Expert Opin Drug Metab Toxicol 8:505-13. 2012..Thus, additional data are required to establish the full clinical profile of this compound and its potential advantages over antiresorptive agents commonly in use for the treatment of osteoporosis... - Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosisLuigi Gennari
University of Siena, Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Viale Bracci 1, 53100 Siena, Italy
Expert Opin Investig Drugs 15:1091-103. 2006..Dose modelling from Phase II studies allowed the selection of lasofoxifene 0.25 mg/day as the lowest fully effective dose... - Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosisLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte, Siena, Italy
Drugs Today (Barc) 42:355-67. 2006..25 mg/day as the lowest fully effective dose. The compound shows a favorable safety profile and is currently in phase III development for the prevention and treatment of osteoporosis in postmenopausal women... - Lasofoxifene (Pfizer)Luigi Gennari
University of Siena, Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Policlinico Le Scotte, Siena, Italy
Curr Opin Investig Drugs 6:1067-78. 2005..In August 2004, Pfizer submitted a New Drug Application to the Food and Drug Administration (FDA) seeking approval of lasofoxifene for the treatment of osteoporosis; however, in September 2005, the FDA issued a non-approvable letter... - Prevalence of Paget's disease of bone in ItalyLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, and Department of Radiology, U O A I S Giovanni Battista Hospital of Torino, Italy
J Bone Miner Res 20:1845-50. 2005..7% to 2.4%, were higher in males than in females, and slightly differed between the two towns. Unlike previous studies in populations of British descent, no secular trend for a decreasing prevalence emerged... - Oral ibandronic acidLuigi Gennari
University of Siena, Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Policlinico Le Scotte, 53100 Siena, Italy
IDrugs 8:155-69. 2005..Roche and its Japanese subsidiary Chugai Pharmaceutical Co Ltd, in collaboration with GlaxoSmithKline plc, have also developed the formulation for the treatment of osteoporosis... - Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE reviewL Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Faculty of Medicine, University of Siena, 53100 Siena, Italy
Am J Epidemiol 161:307-20. 2005..At the moment, no recommendations for population-based screening can be made... - Aromatase activity and bone homeostasis in menLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences, and Biochemistry, University of Siena, Siena 53100, Italy
J Clin Endocrinol Metab 89:5898-907. 2004.... - Ospemifene HormosLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scott, 53100 Siena, Italy
Curr Opin Investig Drugs 5:448-55. 2004..By November 2003, Hormos had advanced the drug into phase II/III testing for both indications... - Paget's disease of bone in ItalyLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
J Bone Miner Res 21:P14-21. 2006..These results confirm PDB to be the most common bone remodeling disorder in elderly people in Italy, excluding osteoporosis... - Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic reviewLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy
Expert Opin Pharmacother 8:537-53. 2007..This review analyses major pharmacogenetic studies of polymorphisms in steroid hormone receptor genes... - Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of developmentLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte, Siena, Italy
Drugs Aging 24:361-79. 2007..Clinical efficacy data from ongoing phase III trials are awaited so that a true understanding of the therapeutic potential of these compounds can be obtained... - Aromatase activity and bone lossLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
Adv Clin Chem 54:129-64. 2011..Moreover, with aging, individual differences in aromatase activity and thus in estrogen levels may significantly affect bone loss and fracture risk in both genders... - SQSTM1 gene analysis and gene-environment interaction in Paget's disease of boneLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
J Bone Miner Res 25:1375-84. 2010..84 +/- 2.5 versus 2.76 +/- 2.2, p < .05). Overall, these data suggest that animal-related factors may be important in the etiology of PDB and may interact with SQSTM1 mutations in influencing disease severity... - Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifeneLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
Clin Interv Aging 5:19-29. 2010.... - The use of intravenous aminobisphosphonates for the treatment of Paget's disease of boneLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, 53100 Siena, Italy
Mini Rev Med Chem 9:1052-63. 2009..Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment outcomes, allowing a more effective and convenient management of this disorder... - Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophyLuigi Gennari
University of Siena, Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Viale Bracci 1, 53100 Siena, Italy
Expert Opin Pharmacother 10:2209-20. 2009..With its increased potency and efficacy on the prevention of nonvertebral fractures and its positive effects on the vagina, this new SERM may represent an alternative therapy for osteoporosis in postmenopausal women... - Ospemifene use in postmenopausal womenLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Viale Bracci 1, Policlinico Le Scotte, Siena, Italy
Expert Opin Investig Drugs 18:839-49. 2009..However, currently available SERMS are also responsible for side effects such as thromboembolic disorders, or gynecological symptoms (especially vaginal dryness and hot flushes)... - Update on the pharmacogenetics of the vitamin D receptor and osteoporosisLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Viale Bracci 1, 53100 Siena, Italy
Pharmacogenomics 10:417-33. 2009..This review analyzes major pharmacogenetic studies of polymorphisms in the vitamin D receptor gene and osteoporosis... - Raloxifene in breast cancer preventionLuigi Gennari
University of Siena, Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Viale Bracci 1, 53100 Siena, Italy
Expert Opin Drug Saf 7:259-70. 2008..This compound was first approved in different countries for the prevention and treatment of osteoporosis... - Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly menLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, 53100 Siena, Italy
J Clin Endocrinol Metab 88:5327-33. 2003..In conclusion, results from the present study indicate an important role of estrogens, and particularly of the ability to aromatize T to E(2), in the regulation of bone loss and bone metabolism in elderly men... - Genetics of osteoporosis: role of steroid hormone receptor gene polymorphismsL Gennari
Department of Internal Medicine, University of Florence, Viale Pieraccini 6, 50135 Florence, Italy
J Steroid Biochem Mol Biol 81:1-24. 2002.... - PTH in the pathogenesis and treatment of glucocorticoid-induced osteoporosisC Gennari
Institute of Internal Medicine, University of Siena, Italy
Front Horm Res 30:184-97. 2002 - Perspectives in the treatment and prevention of osteoporosisL Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
Drugs Today (Barc) 45:629-47. 2009..This review summarizes the effects of existing treatment options and of promising new therapies for osteoporosis prevention and treatment... - Calcium and vitamin D nutrition and bone disease of the elderlyC Gennari
Institute of Internal Medicine, University of Siena, Italy
Public Health Nutr 4:547-59. 2001..This is an effective, safe and cheap means of preventing osteoporotic fractures... - Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of boneDaniela Merlotti
Department of Internal Medicine, Endocrine Metabolic Sciences, and Biochemistry, University of Siena, Siena, Italy
J Bone Miner Res 26:512-8. 2011.... - Comparison of different intravenous bisphosphonate regimens for Paget's disease of boneDaniela Merlotti
Department of Internal Medicine, Endocrine, Metabolic Sciences, and Biochemistry, University of Siena, Siena, Italy
J Bone Miner Res 22:1510-7. 2007..Single neridronate and zoledronate infusion showed a similar efficacy in up to 90% of patients nonresponders to pamidronate... - Characteristics and familial aggregation of Paget's disease of bone in ItalyDaniela Merlotti
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena, Italy
J Bone Miner Res 20:1356-64. 2005..Familial aggregation was observed in 15% of cases... - A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolismLuigi Gennari
Department of Internal Medicine, University of Florence, 50139 Florence, Italy
J Clin Endocrinol Metab 89:2803-10. 2004..In conclusion, differences in estrogen levels due to polymorphism at the aromatase CYP19 gene may predispose men to increased age-related bone loss and fracture risk... - The effects of zoledronic acid on serum lipids in multiple myeloma patientsAlessandro Gozzetti
Division of Hematology and Transplants, Policlinico Santa Maria Le Scotte, University of Siena, Siena 53100, Italy
Calcif Tissue Int 82:258-62. 2008..In conclusion, ZA given intravenously at high doses in patients with smoldering myeloma seems to be able to modify the lipid profile with an improvement of atherosclerotic risk index... - The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levelsGiuseppe Martini
Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Internal Medicine, University of Siena, Siena, Italy
Thyroid 18:455-60. 2008.... - Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in menStefano Gonnelli
Department of Internal Medicine, Endocrine Metabolic Science and Biochemistry, University of Siena, Policlinico Le Scotte, Viale Bracci 2, 53100 Siena, Italy
Osteoporos Int 16:963-8. 2005..QUS seems to play an independent and complementary role, with respect to DXA, in order to enhance the power for predicting osteoporotic fractures in men... - Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteriesAlberto Palazzuoli
Division of Cardiology, Institute of Internal Medicine and Metabolic Diseases, University of Siena, Siena, Italy
Am J Cardiol 96:1705-10. 2005..BNP was also associated with multivessel disease and left anterior descending involvement... - Dual X-ray and laser absorptiometry of the calcaneus: comparison with quantitative ultrasound and dual-energy X-ray absorptiometryGiuseppe Martini
Department of Internal Medicine and Metabolic Diseases, University of Siena, Siena, Italy
J Clin Densitom 7:349-54. 2004.... - Infection by CagA-positive Helicobacter pylori strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalitiesN Figura
Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Italy
Dig Dis Sci 47:831-6. 2002..pylori infection with IHD. Coronary vessels of IHD patients infected by CagA-positive H. pylori strains may be damaged more severely than those of uninfected patients... - Bazedoxifene for the prevention of postmenopausal osteoporosisLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte 53100 Siena, Italy
Ther Clin Risk Manag 4:1229-42. 2008..These properties and the safety profile of this combination, if confirmed long-term in ongoing phase 3 trials, might significantly affect the way women and physicians approach menopause and its related disorders... - HLA antigens and primary osteoarthritis of the handDaniela Merlotti
Department of Internal Medicine, University of Siena, Italy
J Rheumatol 30:1298-304. 2003..Haplotype analysis showed an association of B35-DQ1, B40-DQ1, and DR2-DQ1 with increased OA risk. CONCLUSION: Our results suggest a role of the HLA system in the etiopathogenesis of primary OA of the hand... - Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertensionAlberto Palazzuoli
Department of Internal Medicine and Metabolic Disease, Section of Cardiology, University of Siena
Blood Press 13:14-9. 2004..Twenty-one male sprinter runners were checked during a period of training and compared with 19 young patients suffering from mild hypertension and 15 healthy controls matched for gender and body size... - Quantitative ultrasound in the assessment of skeletal status in uremic patientsA Montagnani
Institute of Internal Medicine, University of Siena, Italy
J Clin Densitom 2:389-95. 1999..Our results seem to demonstrate that US parameters are a useful tool in the assessment of skeletal status in patients on maintenance dialysis... - IgG and IgM antiganglioside M1 antibodies in primary Sjogren's syndrome with and without peripheral neuropathyN Giordano
Department of Internal Medicine, University of Siena, Viale Bracci 1, 53100 Siena, Italy
Clin Rheumatol 22:256-8. 2003 - Aerobic exercise training fails to reduce blood pressure in nondipper-type hypertensionR Nami
Department of Cardiology, Institute of Internal Medicine, University of Siena, Italy
Am J Hypertens 13:593-600. 2000.... - Quantitative ultrasound and bone mineral density in patients with primary hyperparathyroidism before and after surgical treatmentS Gonnelli
Institute of Internal Medicine, University of Siena, Italy
Osteoporos Int 11:255-60. 2000..The combined use of BMD and QUS could improve the assessment of skeletal status in patients with PHPT before and after surgery... - CagA-positive Helicobacter pylori infection may increase the risk of food allergy developmentN Figura
Institute of Internal Medicine, University of Siena, Italy
J Physiol Pharmacol 50:827-31. 1999..28 kU/L (SD 3.93), vs. 1.99 kU/L (SD 1.53), P = 0.002, 95% confidence interval = 0.61 to 2.53). Infection by CagA-positive H. pylori increases the risk of developing food allergy... - Acute hepatitis induced by cyproterone acetateN Giordano
Institute of Internal Medicine, University of Siena, Italy
Ann Pharmacother 35:1053-5. 2001..To report a case of acute hepatitis resulting from the use of cyproterone acetate, an adjuvant treatment for prostate cancer... - The infection by Helicobacter pylori strains expressing CagA is highly prevalent in women with autoimmune thyroid disordersN Figura
Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Italy
J Physiol Pharmacol 50:817-26. 1999..0%) than that in controls (8/33, or 24.2%) (P = 0.006, OR = 3.99, RR = 2.31). The other tests gave negative or inexplicable results. In conclusion: CagA-positive H. pylori infection increases the risk of ATD development... - Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronateA Montagnani
Institute of Internal Medicine, Policlinico Le Scotte, University of Siena, Viale Bracci, 53100 Siena, Italy
Bone 32:15-9. 2003.... - Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal studyA Montagnani
Department of Internal Medicine, University of Siena, Italy
Bone 32:427-33. 2003..05) for both BMD-LS and BMD-Fn only at Month 12. In conclusion our results, although obtained from a small sample of postmenopausal hypercholesterolemic women, suggest a probable positive effect of simvastatin on bone formation and BMD... - Food allergy and Helicobacter pylori infectionN Figura
Institute of Internal Medicine, University of Siena, Italy
Ital J Gastroenterol Hepatol 31:186-91. 1999..Inflammatory processes, such as Helicobacter pylori-associated gastritis, could alter the integrity of the gastric barrier, increase the mucosal permeability, and enhance crossing of food antigens which may stimulate allergic reactions... - Alendronate treatment in men with primary osteoporosis: a three-year longitudinal studyS Gonnelli
Department of Internal Medicine, Endocrine Metabolic Science and Biochemistry, University of Siena, Italy
Calcif Tissue Int 73:133-9. 2003..BMD at the lumbar spine appears to be the best method for monitoring the effect of alendronate on bone mass in osteoporotic men... - Hyperuricemia and gout in thyroid endocrine disordersN Giordano
Institute of Internal Medicine, University of Siena, Italy
Clin Exp Rheumatol 19:661-5. 2001..The present study evaluates the prevalence of hyperuricemia and gout in patients affected by primary hypothyroidism and hyperthyroidism... - Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal studyS Gonnelli
Institute of Internal Medicine, University of Siena, Italy
Osteoporos Int 13:415-21. 2002..2 years for BMD, SOS, BUA and Stiffness respectively. Therefore, although the spinal BMD remains the optimal method, QUS at the heel, and in particular Stiffness, seems to be a sensitive tool for monitoring the response to alendronate... - Helicobacter pylori infection and infertilityN Figura
Institute of Internal Medicine, University of Sienna, Sienna, Italy
Eur J Gastroenterol Hepatol 14:663-9. 2002..pylori antibodies in samples of follicular fluid, vaginal secretions and sperm; and (3) the existence of a structural homology between a major spermatozoa protein, tubulin, and H. pylori proteins... - Usefulness of bone quantitative ultrasound in management of osteoporosis in menA Montagnani
Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Viale Bracci, 53100 Siena, Italy
J Clin Densitom 4:231-7. 2001..In conclusion, our data show that QUS parameters are reduced in osteoporotic males; however, only BTT was comparable to DXA parameters in the prediction of fracture risk in men... - Graphic trace analysis of ultrasound at the phalanges may differentiate between subjects with primary hyperparathyroidism and with osteoporosis: a pilot studyA Montagnani
Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Italy
Osteoporos Int 13:222-7. 2002..This suggests that the QUS signal could be a useful instrument in discriminating and studying some of the bone alterations typical of metabolic bone diseases... - Aromatase activity and bone loss in menDaniela Merlotti
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, Viale Bracci 1, 53100 Siena, Italy
J Osteoporos 2011:230671. 2011..Moreover, with aging, individual differences in aromatase activity may significantly affect bone loss and fracture risk in men... - Lasofoxifene: Evidence of its therapeutic value in osteoporosisLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scotte 53100 Siena, Italy
Core Evid 4:113-29. 2010..PLACE IN THERAPY: With its increased potency and efficacy on the prevention of nonvertebral fractures lasofoxifene may be an alternative and cost-effective therapy for osteoporosis in postmenopausal women... - Dual X-ray absorptiometry and bone ultrasonography in patients with Rett syndromeC Cepollaro
Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Italy
Calcif Tissue Int 69:259-62. 2001..Whatever the cause, girls with RS present abnormal bone status with an increase in the risk of fracture... - Left ventricular diastolic function improvement by carvedilol therapy in advanced heart failureAlberto Palazzuoli
Department of Internal Medicine and Metabolic Diseases, Section of Cardiology, University of Siena, Siena, Italy
J Cardiovasc Pharmacol 45:563-8. 2005..These changes remained significant after 1 year of therapy together with improvement in systolic function... - Osteoporosis in menLuigi Gennari
Department of Internal Medicine, Endocrine Metabolic Sciences and Biochemistry, University of Siena, Siena 53100, Italy
Endocrinol Metab Clin North Am 36:399-419. 2007..The purpose of this article is to review what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights about the causes, pathogenesis, and treatment of osteoporosis in men... - Long-term treatment with calcitonin in osteoporosisC Gennari
Institute of Internal Medicine and Medical Pathology, University of Siena, Italy
Horm Metab Res 25:484-5. 1993..Reported results of long-term calcitonin treatment demonstrated that it is possible to delay or to avoid the "resistance" to calcitonin by the cyclical or discontinued administration of the hormone... - Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italian womenM Montomoli
Institute of Internal Medicine, State University of Siena, Siena, Italy
Eur J Clin Nutr 56:21-30. 2002..To evaluate a food frequency questionnaire assessing calcium intake in women... - Genetic markers of osteoarticular disorders: facts and hopesM L Brandi
Department of Medicine, University of Florence, Viale Morgagni 85, 50135 Florence, Italy
Arthritis Res 3:270-80. 2001.... - Analgesic effect of calcitonin in osteoporosisC Gennari
Institute of Internal Medicine, University of Siena, Siena, Italy
Bone 30:67S-70S. 2002..In support of this hypothesis are some observations of an analgesic effect obtained by direct epidural or subaracnoidal injection of calcitonin in humans... - Bona fide genetic associations with bone mineral densityJoel N Hirschhorn
N Engl J Med 358:2403-5. 2008 - Osteoporosis in men: pathophysiology and treatmentLuigi Gennari
College of Physicians and Surgeons, 630 W 168th Street, New York, NY 10032, USA
Curr Rheumatol Rep 9:71-7. 2007..This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men... - Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysisJohn P A Ioannidis
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Greece
J Bone Miner Res 17:2048-60. 2002..In summary, we have found that XX homozygotes may have higher BMD and also a decreased risk of fractures when compared with carriers of the x allele, whereas the PvuII polymorphism is not associated with either BMD or fracture risk... - Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern ItalyDomenico Rendina
Department of Clinical and Experimental Medicine, Federico II University Medical School, Naples, Italy
J Bone Miner Res 21:1828-35. 2006..This peculiar pattern might be traced to genetic predisposition and/or to the abnormal impact of a still undefined environmental trigger... - The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myelomaGiuseppe Martini
Haematologica 91:1720-1. 2006..In treated subjects we found an increase of OPG accounting for an effect of ZA on osteoblast and/or bone marrow stromal cells together with the direct effect on osteoclasts... - Osteoporosis in men: pathophysiology and treatmentLuigi Gennari
College of Physicians and Surgeons, 630 W 168th Street, New York, NY 10032, USA
Curr Osteoporos Rep 5:22-8. 2007..This article reviews what is known about the factors in men that lead to acquisition, maintenance, and loss of bone, as well as new insights into causes, pathogenesis, and treatment of osteoporosis in men...